A Triton Market Research report has determined that the CRISPR market in the Middle East and Africa will prosper at CAGR of 24.08% during the projected period 2019-2028.
The countries scrutinized in the Middle East and Africa market are:
• Turkey
• United Arab Emirates
• South Africa
• Saudi Arabia
• Rest of Middle East & Africa
Turkey is part of the Cartagena Protocol on Biosafety, which is an agreement aiming to ensure the safe handling of living modified organisms. The Biosafety Law and its associated rules, which were implemented in September 2010, regulate biosafety applications in Turkey. Although the country typically does not allow the use of genetically modified organisms for food, the biosecurity council in Turkey approved the utility of three varieties of genetically modified soybeans. Such conformation to the increasing use of genetically modified organisms for the foods is expected to prosper the demand for the CRISPR (Clustered Regularly Interspaced Short Palindrome Repeats) market in Turkey, thereby growing the market growth.
It is reported that the Antiviral Gene Therapy Research Unit (AGTRU) at Wits University is currently undertaking research activities to develop a cure for hepatitis B, which is a virus that destroys the liver. The research team made use of CRISPR-Cas9 and TALENS gene-editing technique to combat the virus. The team has also been working on gene editing techniques against tuberculosis, another major disease in South Africa. These developments in the field of gene therapy are likely to drive the CRISPR market growth in South Africa.
Established in 1987, Integrated DNA Technologies Inc is a company that is involved in the development and manufacturing of custom oligonucleotides for the research & diagnostics life science market. It provides its products to different areas of academic research, and pharmaceutical & biotechnological development. It is specialized in the areas of gene splicing, DNA sequencing, transcription profiling, SNP detection, and DNA amplification. The company has business operations in the Middle East.
Some of the key companies in the CRISPR market are Intellia Therapeutics Inc, Cellectis, Sigma-Aldrich (Merck KGaA), GenScript, New England Biolabs, GeneCopoeia Inc, Origene Technologies Inc, Addgene, Horizon Discovery Ltd, Applied StemCell, Thermo Fisher Scientific Inc, Editas Medicine, DiaCarta, Caribou Biosciences Inc, Sangamo Therapeutics, Transposagen Bio (Hera BioLabs), Genedata AG, Precision Biosciences, Lonza, Integrated DNA Technologies Inc and CRISPR Therapeutics.